These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15250065)

  • 61. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treating Low Vitamin D Levels Is Ineffective in Postmenopausal Women.
    Shaughnessy AF
    Am Fam Physician; 2016 Feb; 93(4):315. PubMed ID: 26926821
    [No Abstract]   [Full Text] [Related]  

  • 63. [Vitamin D status in osteoporotic postmenopausal women taking oral recommended vitamin D supplementation].
    Ivorra J; Valls E; Fernández-Llanio Comella N; Chalmeta Verdejo I; Oliver Oliver MJ; Román Ivorra JA
    Med Clin (Barc); 2012 Mar; 138(5):199-201. PubMed ID: 22197363
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
    Cranney A; Wells G; Willan A; Griffith L; Zytaruk N; Robinson V; Black D; Adachi J; Shea B; Tugwell P; Guyatt G;
    Endocr Rev; 2002 Aug; 23(4):508-16. PubMed ID: 12202465
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
    Ozdemir F; Rodoplu M
    Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Alendronate: a bisphosphonate for treatment of osteoporosis.
    Kirk JK; Spangler JG
    Am Fam Physician; 1996 Nov; 54(6):2053-60. PubMed ID: 8900364
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Drugs for prevention and treatment of postmenopausal osteoporosis.
    Med Lett Drugs Ther; 2000 Oct; 42(1090):97-100. PubMed ID: 11035622
    [No Abstract]   [Full Text] [Related]  

  • 71. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis.
    Dursun N; Dursun E; Yalçin S
    Int J Clin Pract; 2001 Oct; 55(8):505-9. PubMed ID: 11695068
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.
    Davis L
    J Nurse Midwifery; 1998; 43(5):395-6. PubMed ID: 9841259
    [No Abstract]   [Full Text] [Related]  

  • 73. Letter re: 25-OH-vitamin D assays.
    Fradinger EE
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6337-8; author reply 6338. PubMed ID: 16275982
    [No Abstract]   [Full Text] [Related]  

  • 74. A 73-year-old woman with osteoporosis.
    Greenspan SL
    JAMA; 1999 Apr; 281(16):1531-40. PubMed ID: 10227324
    [No Abstract]   [Full Text] [Related]  

  • 75. Vitamin D for the treatment of osteoporosis.
    Nakamura T
    Osteoporos Int; 1997; 7 Suppl 3():S155-8. PubMed ID: 9536323
    [No Abstract]   [Full Text] [Related]  

  • 76. Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy.
    Ortego-Jurado M; Ríos-Fernández R; Callejas-Rubio JL; Gonzalez-Gay MA; Ortego-Centeno N
    Osteoporos Int; 2014 Aug; 25(8):2157-8. PubMed ID: 24803328
    [No Abstract]   [Full Text] [Related]  

  • 77. Letter to the Editor: Comment on "Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study" by Kratz E., et al.
    Salvatori R
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L107. PubMed ID: 26544657
    [No Abstract]   [Full Text] [Related]  

  • 78. Response to the Letter by Salvatori R.
    Krantz E; Trimpou P; Landin-Wilhelmsen K
    J Clin Endocrinol Metab; 2015 Nov; 100(11):L108. PubMed ID: 26544658
    [No Abstract]   [Full Text] [Related]  

  • 79. Bone: Antifracture efficacy of growth hormone-confirmation at long last.
    Holmes D
    Nat Rev Endocrinol; 2015 Nov; 11(11):631. PubMed ID: 26391976
    [No Abstract]   [Full Text] [Related]  

  • 80. Association between vitamin D and falls in young postmenopausal women.
    Palacios S
    Menopause; 2016 Mar; 23(3):239-40. PubMed ID: 26818014
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.